High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Researchers develop first plant-based gel to support organoid growth for biomedical applications

Monash University researchers have created the world's first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of studies into cancer and COVID-19.

25 Nov 2020

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Researchers have developed a fluorescent reporter gene-bearing recombinant form of SARS-CoV-2, which is capable of replication.

23 Nov 2020

Ethacridine blocks SARS-CoV-2 with a distinct mode of action

Now, researchers from the University of California, San Francisco, and Stanford University, California, USA, reported a safe and potent antiseptic for use in humans named ethacridine, which effectively inhibits SARS-CoV-2 even at very low concentrations of EC50 ~ 0.08 µM. Their work has is published on the preprint server bioRxiv*.

1 Nov 2020

Transcriptomics identifies possible COVID-19 therapies

By using a diverse set of transcriptomic SARS-CoV-2 signatures, US researchers put to use their previously developed drug repositioning pipeline to pinpoint potential drug candidates for the treatment of coronavirus disease (COVID-19). The study is currently available on bioRxiv preprint server.

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

New inhibitor of SARS-CoV-2 RNA translation

As the search for effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibitors continues, a recent study by Yale University School of Medicine researchers published on the preprint server bioRxiv in October 2020 reports the inhibitory effect of the drug merofloxacin on frameshifting during SARS-CoV-2 replication.

26 Oct 2020

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

Sanford Burnham Prebys receives NIH grant to identify new therapies for mental disorders

Sanford Burnham Prebys Medical Discovery Institute has been awarded a $4.5 million grant from the National Institutes of Health (NIH) to identify new therapies for mental health disorders.

6 Aug 2020

Novel drug candidate offers a major advance in the treatment for diabetes

The University of Alabama at Birmingham and Southern Research have discovered a new drug candidate that offers a major advance in the treatment for diabetes.

28 Jul 2020

High-quality lab procedures crucial to discovery of effective drugs

In their quest to find new drugs to treat deadly diseases, scientists study millions of molecules at high speed at the same time. Often it is enzymes that are investigated as targets in these 'high-throughput' screenings.

21 Jul 2020

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

Sanford Burnham Prebys Medical Discovery Institute has received an award from the California Institute for Regenerative Medicine to advance promising drug candidates for COVID-19.

21 Jul 2020

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, and Heriot-Watt University, a specialist, pioneering Scottish University, today announced they have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency.

From Sphere Fluidics 20 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Now, an intriguing new study out of the University of Wisconsin-Milwaukee reveals that numerous small molecule drugs like the proton pump inhibitors omeprazole and rabeprazole bind the important Mac1 domain on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.

8 Jul 2020

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

The cover for issue 27 of Oncotarget features "Bimodal imaging examples of control and treated tumors (red) before and after the treatment period," by Browning, et al. and reported that the authors developed a 3-dimensional bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) tumors together with a microscopy assay to test chemotherapeutic effects in tissue.

7 Jul 2020

Cell 'membrane on a chip' could help test potential drug candidates for COVID-19

Researchers have developed a human cell 'membrane on a chip' that allows continuous monitoring of how drugs and infectious agents interact with our cells, and may soon be used to test potential drug candidates for COVID-19.

6 Jul 2020

New approach holds incredible potential for developing new therapeutics

Nearly every drug that is, or has ever been, used was derived from nature -- harnessing compounds created by organisms over eons to fight diseases. But decades ago, biochemists postulated that it might be possible to design a new drug from scratch by linking up amino acids in precise ways.

30 Jun 2020

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

Researchers at the University of Texas Medical Branch, Galveston, have developed a new platform that can rapidly test neutralizing antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and perform high-throughput screening of potential antiviral agents.

24 Jun 2020

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

Group 42 (G42), a leading AI and Cloud Computing company based in the United Arab Emirates, and Oxford Nanopore Technologies, an advanced sequencing technology company based in the United Kingdom, announced today they have developed an unprecedented population-scale technology that rapidly and accurately detects SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

New genetic engineering technique sets the stage for advances in medicine and beyond

From bacteria-made insulin that obviates the use of animal pancreases to a better understanding of infectious diseases and improved treatments, genetic engineering of bacteria has redefined modern medicine. Yet, serious limitations remain that hamper| progress in numerous other areas.

30 May 2020

High throughput screening News and Research

Further Reading

Researchers develop first plant-based gel to support organoid growth for biomedical applications

Researchers develop recombinant SARS-CoV-2 model to aid vaccine and antiviral research

Ethacridine blocks SARS-CoV-2 with a distinct mode of action

Transcriptomics identifies possible COVID-19 therapies

Small molecules block SARS-CoV-2 spike-ACE2 attachment

New inhibitor of SARS-CoV-2 RNA translation

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Sanford Burnham Prebys receives NIH grant to identify new therapies for mental disorders

Novel drug candidate offers a major advance in the treatment for diabetes

High-quality lab procedures crucial to discovery of effective drugs

Sanford Burnham Prebys receives CIRM award to advance promising drug candidates for COVID-19

Sphere Fluidics and Heriot-Watt University collaborate to develop next generation droplet generator instrumentation

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Small molecule drugs binding Mac1 domain of SARS-CoV-2

Researchers develop bioprinted skin model of cutaneous squamous cell carcinoma

Cell 'membrane on a chip' could help test potential drug candidates for COVID-19

New approach holds incredible potential for developing new therapeutics

New assay rapidly tests SARS-CoV-2 neutralization and screens antivirals

G42 and Oxford Nanopore co-develop population-scale technology to detect SARS-CoV-2

New genetic engineering technique sets the stage for advances in medicine and beyond

Lab Diagnostics and Automation - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News